A Study to Assess the Efficacy and Safety of CMK389 in Patients With Moderate to Severe Atopic Dermatitis.

NCT04836858 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

71

Enrollment

INDUSTRY

Sponsor class

Conditions

Atopic Dermatitis

Interventions

BIOLOGICAL: CMK389
BIOLOGICAL: Placebo

Sponsor

Novartis Pharmaceuticals